ClinicalTrials.gg
CompletedNCT06944379Updated Oct 9, 2026

ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

A Phase 1 interventional study of ORKA-002 and Placebo in Healthy Volunteers, sponsored by Oruka Therapeutics, Inc.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Oruka Therapeutics, Inc. · Phase 1, Interventional, and Other

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.

Read the detailed description

This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) of ORKA-002 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-002 dose will be administered by a subcutaneous injection.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • ORKA-002
  • Phase 1
03

In context

Lead sponsor

Oruka Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy male or female participants
  2. 18 to 65 years (inclusive) with a (BMI) 18 to 32 kg/m2 at Screening
  3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit(s)/s defined in the protocol
  4. Using two methods of (one being highly effective) from admission through the end of the study

Key Exclusion Criteria:

  1. Any medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.
  2. Known history of illicit drug use or drug abuse or harmful alcohol use
  3. Known history of frequent tobacco or vaping use within 2 years prior to screening
  4. Unwilling to abstain from regular, continuous alcohol use or tobacco use as per protocol
  5. History of severe allergic reactions or
  6. Actively nursing, lactating, pregnant, or plans to be pregnant
  7. Use of any drug therapy within 30 days prior to enrollment
  8. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ORKA-002

    Subcutaneous (SC) injection of ORKA-002

    Drug: ORKA-002

  • Placebo comparator
    Placebo

    Subcutaneous (SC) injection of placebo comparator

    Other: Placebo

Interventions

  • ORKA-002 is supplied as sterile solution to be administered by SC injection

  • OtherPlacebo

    Placebo solution to be administered at a matching volume by SC injection

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events

    Incidence of treatment-emergent adverse events and clinically significant changes from baseline in vital signs, electrocardiograms, and clinical laboratory parameters

    Time frame: Day 1 through 1 year

Secondary outcomes

  1. Maximum observed serum concentration of ORKA-002

    Cmax of ORKA-002

    Time frame: Day 1 through 1 year

  2. Time to Cmax (Tmax) of ORKA-002

    Tmax of ORKA-002

    Time frame: Day 1 through 1 year

  3. Area under the serum concentration-time curve (AUC) of ORKA-002

    Area under the curve from the time of dosing to infinity (AUC0-inf)

    Time frame: Day 1 through 1 year

  4. Terminal elimination half-life (T1/2)

    T1/2 of ORKA-002

    Time frame: Day 1 through 1 year

07

Study locations

1 site
  • Oruka Therapeutics Investigative Site
    Christchurch, New Zealand, New Zealand
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in Aug 2026, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jan 2027 → Aug 2026 and completion Jan 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 25, 2025
StartActual
May 19, 2025
Primary completionActual
Aug 20, 2026was Jan 2027
CompletionActual
Aug 20, 2026was Jan 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Primary completion
Jan 2027→Aug 20, 2026 (actual)
Oct 9, 2026
Study completion
Jan 2027→Aug 20, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Primary completion Jan 2027→Aug 20, 2026 (now actual)
    Study completion Jan 2027→Aug 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06944379
Lead sponsor
Oruka Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
May 19, 2025
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update
Oct 9, 2026

Study contacts

Kyle Breitschwerdt
study director · Oruka Therapeutics, Inc.
Principal Investigator
principal investigator · Oruka Therapeutics Investigative Site

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORKA-002

Start the discussion